New York, NY. The alternative dispute resolution landscape is constantly changing and Nixon Peabody partners are at the forefront of those changes, whether it be looking ahead to which arbitration provisions will best survive attack, or which arbitration forums will best suit the needs of which clients, or which practices produce the best outcomes for clients in arbitration hearings.
Christopher Mason, who leads Nixon Peabody’s arbitration team, has been named to the Executive Advisory Committee of CPR: International Institute for Conflict Prevention & Resolution. CPR is widely recognized as one of the two leading non-profit resources for businesses in arbitration and alternative dispute resolution, whether domestic or international. Mr. Mason, a highly experienced arbitration practitioner and mediator, will be joining several other private lawyers and top in house counsel from major international companies to advise CPR in its mission to spearhead innovation and promote excellence in public and private dispute resolution. Based in Nixon Peabody’s New York City office, Mr. Mason regularly represents corporate trustees, consumer product companies, technology businesses (hardware, software, and services), financial institutions, private equity funds or participants, and industrial companies in state or federal trial and appellate courts, in domestic arbitration and mediation, and in regulatory inquiries.
Nixon Peabody partner and leader of the firm’s health services and life sciences practices, Michele Masucci, has been asked to serve as a member of the Healthcare Dispute Resolution Advisory Council for the other leading non-profit alternative dispute institution in the country, the American Arbitration Association. In this role, she will lend her expertise to help the AAA foster and develop dispute resolution solutions for healthcare businesses and participants. In her practice, Ms. Masucci advises health care industry clients, with particular experience serving as general and special counsel to private equity firms and other investors looking to make investments in the industry. She also provides counsel on the interplay between life sciences companies and the use of their products in a clinical setting.